Intact N-Terminal Propeptide of Type 1 Procollagen

The Intact N-Terminal Propeptide of Type 1 Procollagen (P1NP, also called PINP or procollagen type I N-terminal propeptide) assay quantifies a formation marker that mirrors new type I collagen synthesis. It supports baseline characterization of bone formation status and subsequent assessment of treatment response in osteoporosis, including patients treated with teriparatide and other bone-active agents. P1NP testing is incorporated into follow-up of osteoporosis, Paget disease, and metastatic involvement of bone, where it can aid in gauging the activity of skeletal metastases. In selected contexts, P1NP has also been applied to estimate mortality risk.

Skeletal tissue is in a state of continual remodeling, with osteoclast-mediated resorption balanced by osteoblast-driven formation, and is modulated by calcium homeostasis and endocrine signals. Type I collagen is the principal organic constituent of bone matrix. It is synthesized as procollagen containing N- and C-terminal propeptides that are enzymatically removed during maturation; the intact N-terminal propeptide (P1NP) is relatively stable in circulation and tracks the deposition of new collagen. Accordingly, P1NP functions as a marker of bone formation and, by extension, global bone turnover. P1NP complements bone resorption markers and bone mineral density measurements in the evaluation of metabolic bone disorders such as postmenopausal osteoporosis, Paget disease, and metastatic involvement of bone. Concentrations display diurnal variation, with higher values at night; subsequent specimens should be collected at a consistent time of day for comparison. P1NP is cleared by the liver, and severe hepatic dysfunction can raise circulating levels due to reduced metabolic clearance.